The Peptide Field
Menu

16 FDA label and trial tables · Checked

Vomiting vs placebo, out of 100 people

Zepbound label

Placebo2%
On Zepbound (by dose)8% to 13%

In the Zepbound label, 8% to 13% on Zepbound (by dose) had vomiting. On placebo, 2% did.

See all 16 tablesFrom the label: more on vomiting

Every table that lists vomiting

Each dot is 1 in 100 people.

Reported it Rest of a dose range Did not report it

Filled dots show the low end of a range. Dots are rounded. The exact number is above each grid.

FDA-approved medicines

EgriftaFDA-approved product

Adults with HIV and extra belly fat, less common

Row in the source: Vomiting

Placebo0%
On Egrifta3%
Who was studied
Adults with HIV and lipodystrophy in placebo-controlled trials. 543 got Egrifta and 263 got placebo.
How long
26 weeks
Source
Egrifta WR prescribing information on DailyMed . FDA label revised March 2025.

ForteoFDA-approved product

Women and men with osteoporosis, less common problems

Row in the source: Vomiting

Placebo2.3%
On Forteo3.0%
Who was studied
1,382 adults aged 28 to 86. 691 got Forteo and 691 got placebo. Everyone also took calcium and vitamin D. The middle trial length was 11 months for men and 19 months for women.
How long
11 months (men), 19 months (women)
Source
Forteo prescribing information on DailyMed . FDA label revised August 2026.

MounjaroFDA-approved product

Mounjaro trials in adults with type 2 diabetes

Row in the source: Vomiting

Placebo2%
On Mounjaro (by dose)5% to 9%
Who was studied
Adults with type 2 diabetes in 2 trials. One tested Mounjaro alone. The other added it to long-acting insulin, with or without metformin. 718 adults took Mounjaro in three dose groups and 235 took placebo.
How long
40 weeks
Source
Mounjaro prescribing information on DailyMed . FDA label revised August 2026.

OzempicFDA-approved product

Ozempic trials in adults with type 2 diabetes

Row in the source: Vomiting

Placebo2.3%
On Ozempic (by dose)5.0% to 9.2%
Who was studied
Adults with type 2 diabetes in 2 trials. One tested Ozempic alone. The other added it to long-acting insulin. 521 adults took Ozempic in two dose groups and 262 took placebo.
How long
30 weeks
Source
Ozempic prescribing information on DailyMed . FDA label revised June 2026.

SaxendaFDA-approved product

Saxenda trials in adults with obesity or overweight

Row in the source: Vomiting

Placebo3.9%
On Saxenda15.7%
Who was studied
Adults with obesity or overweight in 5 trials. 3,384 got Saxenda and 1,941 got placebo. 15% had type 2 diabetes. Everyone also got advice on diet and exercise.
How long
32 to 56 weeks, some up to about 3 years
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

SaxendaFDA-approved product

Saxenda trial in teens with obesity

Row in the source: Vomiting

Placebo4.0%
On Saxenda34.4%
Who was studied
Children aged 12 and older with obesity. None had type 2 diabetes. 125 got Saxenda and 126 got placebo.
How long
56 weeks
Source
Saxenda prescribing information on DailyMed . FDA label revised February 2026.

VictozaFDA-approved product

Victoza trials in adults with type 2 diabetes

Row in the source: Vomiting

Placebo2%
On Victoza (by dose)6% to 9%
Who was studied
Adults with type 2 diabetes in 5 trials. The table counts 1,669 adults on Victoza in two dose groups and 661 on placebo.
How long
At least 26 weeks each
Source
Victoza prescribing information on DailyMed . FDA label revised October 2025.

VyleesiFDA-approved product

Premenopausal women with HSDD

Row in the source: Vomiting

Placebo0.2%
On Vyleesi4.8%
Who was studied
1,247 women aged 19 to 56 in two matching trials. 627 got Vyleesi and 620 got placebo.
How long
24 weeks
Source
Vyleesi prescribing information on DailyMed . FDA label revised March 2024.

WegovyFDA-approved product

Wegovy trials in adults with obesity or overweight

Row in the source: Vomiting

Placebo6%
On Wegovy24%
Who was studied
Adults with obesity or overweight in 3 trials. 2,116 got Wegovy and 1,261 got placebo. 19% had type 2 diabetes.
How long
Up to 68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

WegovyFDA-approved product

Wegovy trial in teens with obesity

Row in the source: Vomiting

Placebo10%
On Wegovy36%
Who was studied
Children aged 12 and older with obesity. 133 got Wegovy and 67 got placebo.
How long
68 weeks
Source
Wegovy prescribing information on DailyMed . FDA label revised June 2026.

ZepboundFDA-approved product

Zepbound trials in adults with obesity or overweight

Row in the source: Vomiting

Placebo2%
On Zepbound (by dose)8% to 13%
Who was studied
Adults with obesity or overweight in 2 trials. One trial included only people with type 2 diabetes; the other left them out. 2,519 got Zepbound in three dose groups and 958 got placebo.
How long
Up to 72 weeks
Source
Zepbound prescribing information on DailyMed . FDA label revised August 2026.

Medicines that are not FDA-approved

CagrilintideNo FDA-approved product

Phase 2 weight trial (NCT03856047), less common problems

Row in the source: Vomiting

Placebo3.0%
On cagrilintide (by dose)4.9% to 8.8%
Who was studied
706 adults without diabetes who had obesity, or overweight with high blood pressure or unhealthy blood-fat levels. 506 got cagrilintide and 101 got placebo. A liraglutide group of 99 is not shown.
How long
26 weeks of treatment, side effects counted to week 32
Source
ClinicalTrials.gov posted results . Trial registry results posted July 18, 2023.

RetatrutideNo FDA-approved product

TRIUMPH-1

Row in the source: Vomiting

Placebo4.8%
On retatrutide (by dose)10.6% to 25.3%
Who was studied
Adults without diabetes who had obesity, or overweight and at least one health problem linked to weight.
How long
80 weeks
Source
Lilly early results . Company trial results posted May 21, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

TRIUMPH-2

Row in the source: Vomiting

Placebo4.2%
On retatrutide (by dose)5.5% to 15.7%
Who was studied
Adults with type 2 diabetes and obesity or overweight.
How long
80 weeks
Source
Lilly early results . Company trial results posted July 23, 2026. Company trial results were not yet checked by outside experts when we read them.

RetatrutideNo FDA-approved product

Phase 2 obesity trial (NCT04881760)

Row in the source: Vomiting

Placebo1.4%
On retatrutide (by dose)2.9% to 25.7%
Who was studied
338 adults with obesity, or with overweight and a health problem linked to weight.
How long
48 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted September 13, 2023.

RetatrutideNo FDA-approved product

Phase 2 type 2 diabetes trial (NCT04867785)

Row in the source: Vomiting

Placebo2.2%
On retatrutide (by dose)0% to 16.7%
Who was studied
281 adults with type 2 diabetes. This trial also had a dulaglutide group, which is not shown.
How long
36 weeks
Source
ClinicalTrials.gov posted results . Trial registry results posted July 3, 2023.

More from the labels

These lines are copied from our side effect pages, word for word.

Mounjaro and Zepbound: Stomach and bowel problems

Both labels say most nausea, vomiting, and diarrhea happened while the dose was being raised and became less common over time.

From Mounjaro prescribing information on DailyMed  and Zepbound prescribing information on DailyMed .

Mounjaro: Children with type 2 diabetes

Mounjaro was tested in 97 children aged 10 and older with type 2 diabetes. Side effects were like those in adults, but vomiting, belly pain, and low blood sugar were more common. The 30-week placebo part of that trial tested two doses. Vomiting was reported by 12% to 16% on Mounjaro and 3% on placebo. Belly pain was reported by 15% to 22% on Mounjaro and 9% on placebo.

From Mounjaro prescribing information on DailyMed .

How long were people watched?

Each bar is one set of trials. The dots on this page come only from the time inside each bar.

Stated length Range in the source Some people only No end date given

  1. Egrifta, adults with HIV26 weeks

  2. Forteo, adults with osteoporosis11 months (men), 19 months (women)

  3. Mounjaro, adults with type 2 diabetes40 weeks

  4. Ozempic, adults with type 2 diabetes30 weeks

  5. Saxenda, adults32 to 56 weeks, some up to about 3 years

  6. Saxenda, teens56 weeks

  7. Victoza, adults with type 2 diabetesAt least 26 weeks each

  8. Vyleesi, women24 weeks

  9. Wegovy, adultsUp to 68 weeks

  10. Wegovy, teens68 weeks

  11. Zepbound, adultsUp to 72 weeks

  12. Cagrilintide, phase 226 weeks of treatment, side effects counted to week 32

  13. Retatrutide, TRIUMPH-180 weeks

  14. Retatrutide, TRIUMPH-280 weeks

  15. Retatrutide, phase 2 (obesity)48 weeks

  16. Retatrutide, phase 2 (diabetes)36 weeks

Trials can miss rare harms and harms that take years to appear.

Other side effects

Pick a medicine and side effect

Where the numbers come from

Every number is copied from a table on our side effect pages. Those tables come from FDA labels on DailyMed, results posted on ClinicalTrials.gov, and company trial results. We did not add, total, or rank any number. Rows keep one fixed order: FDA-approved medicines first, then the rest, each in A to Z order.

We group rows by name. For example, “Tiredness (fatigue)” and “Tiredness or weakness (fatigue)” are both under tiredness. Each row still shows its own words from the source.

The tables on this site copy part of each label, such as the most common problems. A problem missing from one table may still have happened.

Report a side effect

You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.

Did this page answer your question?